AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients
Phase 3
Completed
- Conditions
- ManiaBipolar Disorder
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00448578
- Locations
- 🇨🇳
Research Site, Wu han, China
🇨🇳Research Sites, Beijing, China
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 184
- Registration Number
- NCT00444561
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
- First Posted Date
- 2007-03-07
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3029
- Registration Number
- NCT00444275
- Locations
- 🇫🇷
Research Site, Rouen, France
Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)
Phase 3
Completed
- Conditions
- Gastric UlcerDuodenal Ulcer
- Interventions
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2426
- Registration Number
- NCT00441727
- Locations
- 🇹🇭
Research Site, Chiang Mai, Thailand
Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 115
- Registration Number
- NCT00435760
- Locations
- 🇬🇧
Respiratory Clinical Trials Ltd, London, United Kingdom
Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: premixed insulin aspart twice daily (BID)
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 494
- Registration Number
- NCT00434954
- Locations
- 🇩🇪
Research Site, Wolfsburg, Germany
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2207
- Registration Number
- NCT00434967
- Locations
- 🇸🇰
Research Site, Sahy, Slovakia
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 85
- Registration Number
- NCT00431275
- Locations
- 🇺🇸
Research Site, Pittsburgh, Pennsylvania, United States
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary DiseaseCOPD
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1100
- Registration Number
- NCT00430729
- Locations
- 🇬🇧
ALTANA Pharma, Cities in the United Kingdom, United Kingdom
Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic
Phase 4
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00428350
- Locations
- 🇨🇳
Research SIte, Wuhan, Hubei, China
🇨🇳Research Site, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath